Blocking key immune cells could make prostate cancer treatable

	Prostate Cancer
	The latest prostate cancer news from News Medical

	Blocking key immune cells could make prostate cancer treatable Scientists have revealed how certain immune cells may be quietly helping prostate cancer grow - and how blocking them could help the body fight back.

	Guideline-based prostate cancer treatment helps most men outlive the disease Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes other than prostate cancer.

			Study confirms high survival rates for men with low-risk prostate cancer New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 90% were likely to survive their cancer for their remaining life-expectancy.

			Most dairy foods linked to neutral or better health but yogurt stands out for real benefits A major scoping review of recent systematic reviews and meta-analyses finds that most dairy products are either neutral or modestly protective for heart, cancer, metabolic, and mortality outcomes in adults. Yogurt and other fermented dairy consistently show the strongest health associations, while some risks remain for specific cancers.

	Study identifies why some prostate cancers fail to respond to treatment A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.

	Prostate cancer cells evade ferroptosis by accumulating lipid droplets A new research paper was published in Volume 16 of Oncotarget on June 25, 2025, titled "Hypoxia induced lipid droplet accumulation promotes resistance to ferroptosis in prostate cancer."

	Acromegaly linked to higher cancer risk People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, according to a study being presented Monday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

	Multi-pass transmembrane proteins as key targets for cutting-edge R&D Discover the key advantages us using multi-pass transmembrane proteins for drug R&D.

	Rethinking prostate cancer risk in GG1 diagnoses A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell Medicine, University Hospitals Cleveland and Case Western University.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2025